Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
741-760 of 991 trials

Inflammatory Bowel Disease: Risankizumab-800CW Imaging Study

We are investigating the safety and effectiveness of a new imaging agent for patients with Inflammatory Bowel Disease. This study aims to improve how we visualize drug targeting and inflammation in the intestines.

Inflammatory Bowel Disease (IBD)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyInfectious Diseases

Pneumococcal Vaccine Response in Patients Without a Spleen

We are studying how the timing of pneumococcal vaccination affects immune response in patients who have had their spleen removed. This research may help improve vaccination strategies for asplenic individuals.

Asplenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementAllergologyHematologyInfectious Diseases

DENOCHARCOT Trial: DENOsumab for Charcot Foot in Diabetes

We are studying whether DENOsumab can effectively treat acute Charcot foot in people with diabetes. This trial compares the medication to a placebo to assess its impact on health outcomes.

Diabetic Charcot Foot1-2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

CIDP: NVG-2089 Treatment Study

We are evaluating the safety and effectiveness of NVG-2089 for individuals with Chronic Inflammatory Demyelinating Polyneuropathy. This study aims to find out if it can help improve symptoms and overall health.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Staphylococcus Aureus Bacteremia: Shorter Antibiotic Treatment

We are studying whether 4 weeks of antibiotic treatment is as effective as 6 weeks for patients with complicated Staphylococcus aureus bacteremia who have improved after initial therapy.

Staphylococcus aureus Bacteremia6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Heart Failure: Hyperpolarized MRI Study

We are investigating how the heart uses a substance called pyruvate in patients with heart failure. This study aims to see if a new imaging method can improve our understanding of heart metabolism.

Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Erectile Rehabilitation with Sildenafil After Rectal Cancer Surgery

We are studying whether Sildenafil can help men maintain erectile function after proctectomy for rectal cancer. This trial will evaluate its effects on sexual health and quality of life over the year following surgery.

Men Treated with Proctectomy for Rectal Cancer>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementOncologyUrology

Primary Immune Thrombocytopenia: Efgartigimod IV Study

We are testing the safety and effectiveness of efgartigimod IV in adults with primary immune thrombocytopenia. This study will help us understand if it can improve platelet counts and reduce bleeding risks.

Idiopathic Thrombocytopenic Purpura (ITP)>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Advanced Solid Tumors: ALE.P02 Treatment Study

We are investigating a new antibody-drug conjugate, ALE.P02, for adults with certain advanced solid tumors. The study aims to evaluate its safety and how well it may work against these tumors.

Advanced or Metastatic Squamous Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Metastatic Urothelial Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a new combination of livmoniplimab and budigalimab for adults with metastatic urothelial carcinoma who have not responded to prior treatments. The goal is to see if this combination improves survival compared to standard chemotherapy.

Urothelial CarcinomaMetastatic Urothelial CarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Osteogenesis Imperfecta: Losartan Therapy Study

We are investigating the right dose of losartan for older adolescents and adults with Osteogenesis Imperfecta. The study aims to see how it affects bone health and quality of life.

Brittle Bone Disease3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Diffuse Large B-Cell Lymphoma: Zilovertamab Vedotin with R-CHP

We are studying a new treatment combining zilovertamab vedotin with standard therapy for people with diffuse large B-cell lymphoma. The goal is to see if this combination works better than another treatment option.

Diffuse Large B-Cell Lymphoma>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Emicizumab Dosing in Congenital Hemophilia A Patients

We are studying whether personalized dosing of emicizumab can effectively prevent bleeding in patients with congenital hemophilia A compared to standard dosing. This trial also examines the impact on quality of life and treatment costs.

Hemophilia A1-2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Head and Neck Cancer: INBRX-106 with Pembrolizumab

We are studying whether adding INBRX-106 to pembrolizumab helps patients with recurrent or metastatic head and neck cancer. This trial focuses on effectiveness, safety, and quality of life for those with high PD-L1 expression.

Head and Neck Squamous Cell CarcinomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

Kidney Transplant: Belatacept vs. Anticalcineurins

We are studying whether switching from anticalcineurins to Belatacept improves blood vessel function and reduces arterial stiffness in kidney transplant patients. This may help enhance overall cardiovascular health.

Kidney Transplant>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNephrology

Meningococcal Vaccine: Immune Response Study in Transgender and Cisgender Adults

We are investigating how healthy transgender and cisgender individuals aged 18 to 50 respond to the meningococcal serogroup B vaccine. This study aims to understand potential differences in immune responses between these groups.

Healthy Volunteers6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Bone Health: AGA2118 for Postmenopausal Women

We are studying whether AGA2118 can improve bone density in postmenopausal women with low bone mass. The trial compares its effects to a placebo over 12 months.

Postmenopausal OsteoporosisEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinologyOrthopedics and TraumatologyRheumatology

Chronic Spontaneous Urticaria and Hidradenitis Suppurativa: INF904 Study

We are evaluating the safety of an oral medication called INF904 for people with moderate to severe chronic spontaneous urticaria or hidradenitis suppurativa. This study will help us understand how the medication works in the body.

Chronic Spontaneous UrticariaHidradenitis Suppurativa≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Kidney Disease: VX-147 Study for APOL1 Variants

We are testing the safety and effectiveness of VX-147 in adults and children with APOL1-mediated proteinuric kidney disease. The study aims to see if this treatment can improve kidney function and reduce related health risks.

APOL1-mediated Proteinuric Kidney Disease>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNephrology

Lung Cancer Treatment: Adagrasib with Pembrolizumab

We are studying whether adding Adagrasib to standard chemotherapy and Pembrolizumab helps patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The trial will also evaluate safety and quality of life.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncology